Haematologica (May 2024)
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib
- Giacomo Coltro,
- Giulio Capecchi,
- Margherita Maffioli,
- Francesco Mannelli,
- Barbara Mora,
- Alessandro Atanasio,
- Alessandra Iurlo,
- Chiara Maccari,
- Mirko Farina,
- Elena Nacca,
- Marianna Caramella,
- Leonardo Signori,
- Miriam Borella,
- Lorenza Bertù,
- Maria Esposito,
- Paola Guglielmelli,
- Francesco Passamonti,
- Alessandro Maria Vannucchi
Affiliations
- Giacomo Coltro
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Giulio Capecchi
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Margherita Maffioli
- Hematology Unit, ASST Sette Laghi, Ospedale di Circolo, Varese
- Francesco Mannelli
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Barbara Mora
- Hematology Division, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan
- Alessandro Atanasio
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Alessandra Iurlo
- Hematology Division, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan
- Chiara Maccari
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Mirko Farina
- Hematology Unit, ASST Spedali Civili di Brescia, Brescia
- Elena Nacca
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Marianna Caramella
- Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan
- Leonardo Signori
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Miriam Borella
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Lorenza Bertù
- Department of Medicine and Surgery, University of Insubria, Varese
- Maria Esposito
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Paola Guglielmelli
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- Francesco Passamonti
- Hematology Division, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan
- Alessandro Maria Vannucchi
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence
- DOI
- https://doi.org/10.3324/haematol.2024.285098
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
Not available.
